Status:
COMPLETED
Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
Lead Sponsor:
Menoufia University
Conditions:
Cancer of Pancreas
Chemotherapy Effect
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment. This ...
Detailed Description
Metastatic cancer pancreas has been a challenge for oncologists over the years. It is a disease of limited survival and a very poor response to treatment. The median overall survival at five years is ...
Eligibility Criteria
Inclusion
- Histopathological evidence of adenocarcinoma of the pancreas
- Radiological proof of metastatic disease as defined by AJCC
Exclusion
- patients with poor performance status (ECOG 4)
- patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or bilirubin more than 3 mg/dl
- patients with end stage renal disease who are under regular dialysis
- other histologies of pancreatic cancer
- irresectable pancreatic cancer if not metatatic
Key Trial Info
Start Date :
February 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 9 2022
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04769414
Start Date
February 20 2021
End Date
July 9 2022
Last Update
August 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Menoufia University, Faculty of medicine
Shibīn al Kawm, Menoufia, Egypt, 32511